NASDAQ
11.72USD
+0.45 (+3.99%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
441.3M
P/E
—
EPS
—
Beta
0.93
52W range
4.25-25.955
Day range
11.23–11.94
Open
11.40
Prev close
11.27
Volume
936.7K
Avg volume
760.1K
Dividend
0.00
IPO
2024-09-26
https://www.defenseworld.net/2026/07/19/bessemer-group-inc-has-13-26-million-holdings-in-rtx-corporation-rtx.html · 7/19/2026+0.40
https://www.defenseworld.net/2026/07/19/eos-energy-enterprises-nasdaqeose-trading-up-6-time-to-buy.html · 7/19/2026+0.60
https://www.marketbeat.com/instant-alerts/bioage-labs-eyes-key-bge-102-readouts-in-heart-risk-and-diabetic-eye-disease-2026-06-06/ · 6/6/2026+0.60
https://seekingalpha.com/article/4901690-bioage-labs-inc-bioa-discusses-bgeminus-102-clinical-results-and-development-strategy-for · 5/9/2026+0.50
https://www.defenseworld.net/2026/04/26/bioage-labs-touts-phase-1-bge-102-data-citing-86-hs-crp-drop-and-clean-safety-profile.html · 4/26/2026
https://www.prnewswire.com/news-releases/repurchase-of-truecaller-b-shares-in-week-14-2026-302735714.html · 4/7/2026+0.70
https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/ · 1/12/2026+1.00
https://www.prnewswire.com/news-releases/health-canada-grants-authorization-for-leqembi-lecanemab-302594848.html · 10/27/2025+0.80
https://www.fool.com/investing/2025/10/26/bioage-labs-stock-just-soared-does-it-have-fuel-to/ · 10/26/2025+0.60
https://www.globenewswire.com/news-release/2025/08/15/3134242/0/en/BioAge-Labs-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor.html · 8/15/2025+0.80
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
